Evidence map›Paper›PMID 41029085›Full record

ArticleMedicine2025

Novel HBB:c.375_376delAC mutation in a Malay patient with HbE beta-thalassemia intermedia: A case report.

Nur Aisyah Aziz, Ernie Zuraida Ali, Mohd Khairul Nizam Mohd Khalid, Nursaedah Abdullah Aziz, Norodiyah Othman, Faidatul Syazlin Abdul Hamid, Syahzuwan Hassan, Ezalia Esa, Wan Rohani Wan Taib, Khairul Azhar Abu Bakar

Abstract readCase Reports
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nur Aisyah AzizHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0002-4527-0704
Ernie Zuraida AliInborn Error of Metabolism and Genetic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0001-9884-7389
Mohd Khairul Nizam Mohd KhalidInborn Error of Metabolism and Genetic Unit, Nutrition, Metabolism and Cardiovascular Research Centre (NMCRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0001-7200-3102
Nursaedah Abdullah AzizHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0003-1978-5947
Norodiyah OthmanHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0002-2248-3256
Faidatul Syazlin Abdul HamidHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0009-0006-8471-7712
Syahzuwan HassanHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0002-9886-504
Ezalia EsaHematology Unit, Cancer Research Center (CaRC), Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of Health (MOH), Shah Alam, Selangor, Malaysia.ORCID 0000-0001-8699-1017
Wan Rohani Wan TaibFaculty of Health Science, University Sultan Zainal Abidin, Kuala Terengganu, Terengganu, Malaysia.ORCID 0000-0001-9455-5768
Khairul Azhar Abu BakarDepartment of Medicine, Hospital Sultanah Abdul Halim, Ministry of Health (MOH), Sungai Petani, Kedah, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleHemoglobin E beta-thalassemia (HbE-BT) is a prevalent and genetically diverse inherited hemoglobin disorder in Malaysia. While most cases are attributed to known genetic variants, discovering novel mutations is essential for understanding their wide-ranging clinical presentations and underlying genetic heterogeneity. PATIENT CONCERNS: We present the case of a Malay male patient with an intermediate phenotype of HbE-BT whose clinical course was marked by a progression to a transfusion-dependent status, a change triggered by an acute febrile illness. The case highlights the complex challenges of long-term management, including a high risk of iron overload and the significant morbidity and mortality associated with postsplenectomy infections. DIAGNOSES: The patient was referred for a comprehensive DNA analysis of thalassemia syndromes. Full blood count showed hypochromic microcytic anemia (hemoglobin 7.90 g/dL, mean corpuscular volume 66.10 fL). Hemoglobin analysis via capillary electrophoresis revealed a characteristic pattern of HbA (49.1%), HbE (20.6%), and HbF (27.0%). Sanger sequencing subsequently confirmed a compound heterozygous state of HBB:c.79G>A (HbE) and a novel frameshift mutation at codon 124 of the beta-globin gene (HBB:c.375_376delAC). Predictive computational tools further supported the pathogenicity of this new variant, and its data have been submitted to the ITHANET database (IthaID: 4155).

interventionsInitially, the patient's condition was managed with nutritional supplements and intermittent blood transfusions. Following an acute febrile episode at age 26, his clinical condition worsened, necessitating regular monthly blood transfusions to manage severe anemia. He also received subcutaneous chelation therapy to address severe hepatic iron overload. At age 36, he underwent a splenectomy to reduce his transfusion requirements. OUTCOMES: Despite these interventions, the patient passed away at the age of 37 from septic shock and multiorgan failure. This outcome occurred a year after his splenectomy and underscores the critical risk of overwhelming postsplenectomy infection, a significant complication in splenectomized thalassemia patients. LESSONS: Identifying this novel compound heterozygosity contributes to our understanding of the genetic landscape of HbE-BT in Malaysia. This case reinforces the importance of comprehensive molecular analysis for accurate diagnosis, and it has important implications for improving long-term management and genetic counseling strategies for patients with thalassemia syndromes.

Indexed as

beta-Globinsbeta-ThalassemiaHemoglobin EAdultBlood TransfusionFrameshift MutationHumansMalaysiaMaleSplenectomybeta-GlobinsHemoglobin EHbE beta-thalassemiaMalaysiamolecular diagnosisnovel frameshift mutation

Identifiers

PMID41029085
PMCPMC13592936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.